Effects of Two Variants of Roux-en-Y Gastric Bypass on Metabolism Behaviour: Focus on Plasma Ghrelin Concentrations Over a 2-Year Follow-up

Pérez-Romero, Noelia; Serra, Assumpta; Granada, María Luisa; Rull, M; Alastrué, Antonio; Navarro-Díaz, Maruja; Romero, R.; Fernández-Llamazares, J

doi:10.1007/s11695-009-0035-0

Cited by 35 publications

(14 citation statements)

References 59 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these factors, if not all, show dramatic changes after surgically induced WL and may participate with more or less impact in the improvement of IGF1 after surgery. On the other hand, the difference in ghrelin changes observed in our patients depending on the surgical procedure is in agreement with previous studies (37,38,39,40). These results confirm that the resection of the fundus by SG, the main location of ghrelin-producing cells, is the basis of the observed decrease in ghrelin concentrations (38,40).…”

Section: Discussionsupporting

confidence: 93%

IGF1 modifications after bariatric surgery in morbidly obese patients: potential implications of nutritional status according to specific surgical technique

Pellitero

Granada

Martínez

et al. 2013

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Objectives: IGF1 is decreased in morbidly obese (MO) patients and its changes after bariatric surgery weight loss (WL) are not well known. The aim of this study was to analyse IGF1 modifications in MO patients after WL and its relationship to ghrelin and to different types of surgeries. Design: Retrospective follow-up study at the University Medical Center. Methods: One hundred and nine MO patients (age 44.1G9.3, BMI 51.74G8.75 kg/m 2 ) were evaluated at baseline and 1 year after surgery: 28 sleeve gastrectomy (SG), 31 distal modified (m), and 50 ringed (r) Roux-en-Y gastric bypass (RYGBP) surgery. Changes in IGF1, IGFBP3, ratio IGF1:IGFBP3, and ghrelin were evaluated 1 year after surgery. Results: Baseline prevalence of low IGF1 (defined by S.D. IGF1!K2) was 22%, and %WL 1 year after surgery was 34.9G8.9%. There was a significant decrease in IGFBP3 in all the procedures, an increase in IGF1:IGFBP3 ratio in rRYGBP and SG, but total IGF1 only increased significantly in SG. Albumin concentrations decreased in mRYGBP, did not change in rRYGBP, but increased in SG after surgery. Total ghrelin concentrations increased after both RYGBPs and decreased after SG (P!0.05 in all cases). The prevalence of low IGF1 decreased in SG (28.6 vs 10.1%, PZ0.03) and did not change in RYGPBP techniques. The %albumin change was the only dependent variable associated with the % total IGF1 change. Conclusions: Recovery of low IGF1 after bariatric surgery was specifically related to the albumin modifications induced by surgery and was not related to ghrelin modifications.

show abstract

Section: Discussionsupporting

confidence: 93%

IGF1 modifications after bariatric surgery in morbidly obese patients: potential implications of nutritional status according to specific surgical technique

Pellitero

Granada

Martínez

et al. 2013

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Increases in ghrelin levels post-gastric bypass have also been seen (Garcia-Fuentes et al, 2008;Holdstock et al, 2003;Perez-Romero et al, 2010;Ybarra et al, 2009); however this may be associated with active weight loss rather than the surgery itself (Faraj et al, 2003). Several explanations have been proposed for the conflicting findings regarding ghrelin levels following gastric bypass surgery including differences in pre-operative insulin resistance, surgical methods and post-operative vagal nerve dysfunction (Pournaras & le Roux, 2010;Vincent & le Roux, 2008).…”

Section: Ghrelin and Bariatric Surgerymentioning

confidence: 99%

Ghrelin in obesity and endocrine diseases

Scerif

Goldstone

Korbonits

2011

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

“…For patients who are already obese, an effective treatment should be established to promote weight loss and thus prevent or treat its comorbidities, such as CKD. There is increasing evidence that weight loss not only helps to reduce glomerular hyperfiltration and proteinuria [28–30, 34, 58–62] but also attenuates metabolic disorders associated with obesity, such as hypertension [28, 29, 58, 63], altered lipid metabolism [28, 29], insulin resistance and inflammation [28]. Few studies have investigated the fundamental pathophysiological effects that lead to improvement of renal disease in obese patients on low-calorie diets.…”

Section: Therapeutic Approachmentioning

confidence: 99%

Consequences of morbid obesity on the kidney. Where are we going?

Díaz¹

2016

Clin Kidney J

View full text Add to dashboard Cite

Obesity and morbid obesity are modifiable risk factors for the development and progression of kidney disease. Obesity has reached epidemic proportions and is currently an important health problem in Europe, so it is necessary to develop therapeutic and preventive strategies. The obesity-related glomerulopathy has been defined as a secondary form of focal segmental glomerulosclerosis, and its most characteristic feature is glomerulomegaly. The renal evolution of patients with obesity-related glomerulopathy (ORG) who have not been treated is unfavourable. However, morbidly obese patients with ORG that underwent bariatric surgery and drastic weight loss had a better outcome. Many inflammatory factors have been implicated in the pathogenic mechanism of renal disease in obesity. Hypoadiponectinaemia, hyperleptinaemia and hyperaldosteronism have been associated with glomerular injury in obese patients. The application of modern techniques has provided important insights that increase the current understanding of ORG. However, further investigation is needed.

show abstract

Effects of Two Variants of Roux-en-Y Gastric Bypass on Metabolism Behaviour: Focus on Plasma Ghrelin Concentrations Over a 2-Year Follow-up

Cited by 35 publications

References 59 publications

IGF1 modifications after bariatric surgery in morbidly obese patients: potential implications of nutritional status according to specific surgical technique

IGF1 modifications after bariatric surgery in morbidly obese patients: potential implications of nutritional status according to specific surgical technique

Ghrelin in obesity and endocrine diseases

Consequences of morbid obesity on the kidney. Where are we going?

Contact Info

Product

Resources

About